<!DOCTYPE html>
<html>

	<head>
	 <meta charset="UTF-8">
	 <meta name="description" content="This is an awesome website!">
	<title>Bill's BioPharma Watch</title>
	<link href="stylesheet.css" rel="stylesheet">
	</head>
	<body style="background-color:#FAAC58" >
<h1>Bill's BioPharma Watch</h1>
<ul>
	<li><a class="nav-item" href="index.html" >Home</a></li>
	<li><a class="nav-item" href="About.html" >About</a></li>
	<li><a class="nav-item" href="WatchList.html">WatchList</a></li>
	<li><div class="dropdown">
			<button class="dropbtn"style="background-color:#FAAC58;">2020</button>
				<div class="dropdown-content">
				<!--<a href="September.html" >September</a> !-->
				<a href="October.html" >October</a>
				<a href="November.html" >November</a>
				<a href="December.html" >December</a>

			</div>
		</div>
	<li><div class="dropdown">
	<button class="dropbtn"style="background-color:#FAAC58;">2021</button>
		<div class="dropdown-content">
			<a href="Janurary.html" >Janurary</a>
			<a href="February.html" >February</a>
			<a href="March.html" >March</a></li>
			</div>
		</div>

</body>
<div class="tradingview-widget-container">
  <div class="tradingview-widget-container__widget"></div>
  <div class="tradingview-widget-copyright"><a href="https://www.tradingview.com" rel="noopener" target="_blank"></a></div>
  <script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-ticker-tape.js" async>
  {
  "symbols": [
    {
      "description": "",
      "proName": "NASDAQ:GILD"
    },
    {
      "description": "",
      "proName": "HRMY"
    },
    {
      "description": "",
      "proName": "ETON"
    },
    {
      "description": "",
      "proName": "AQST"
    },
    {
      "description": "",
      "proName": "BCRX"
    },
    {
      "description": "",
      "proName": "ZSAN"
    },
    {
      "description": "",
      "proName": "KMPH"
    },
    {
      "description": "",
      "proName": "ADMP"
    },
    {
      "description": "",
      "proName": "FBIO"
    },
    {
      "description": "",
      "proName": "LQDA"
    },
    {
      "description": "",
      "proName": "MNK"
    },
    {
      "description": "",
      "proName": "NYSE:PFE"
    },
    {
      "description": "",
      "proName": "SPPI"
    }
  ],
  "colorTheme": "light",
  "isTransparent": true,
  "displayMode": "adaptive",
  "locale": "en"

}
  </script>
</div>
<p align="center">
		<img width="500" src="DDDoodles_October_drips_styled.png" /></p>

<h2 align="center">FORTRESS BIOTECH INC</h2>

<p>
<center>
	<div class="tradingview-widget-container">
	  <div class="tradingview-widget-container__widget"></div>
	  <div class="tradingview-widget-copyright"><a href="https://www.tradingview.com/symbols/NASDAQ-FBIO/" rel="noopener" target="_blank"></a></div>
	  <script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-symbol-info.js" async>
	  {
	  "symbol": "NASDAQ:FBIO",
	  "width": 1000,
	  "locale": "en",
	  "colorTheme": "light",
	  "isTransparent": false
	}
	  </script>
	</div>
</center>


	<p> 	<b>F</b>ortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. It markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and
jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ala-Scalp and Triderm, which are used for the inflammatory and pruritic manifestations of
corticosteroid-responsive dermatoses; and Ala-Quin, an antibacterial and antifungal cream. The company also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101,
a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for
B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, it develops MB-101 for Glioblastoma (GBM); MB-103 for GBM, and breast cancer and brain
metastases; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small
cell lung cancer; CK-301, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia
ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; Tamid-001, a gene therapy for
mucopolysaccharidosis type I disorder; CNDO-109, a lysate that activates donor natural killer cells; and methazalomide products. The company has collaboration arrangements with some universities,
research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc.
was founded in 2006 and is based in New York, New York. <i>Source Fidelity.com</i>  </p>

<center>
<dl>
  <dt><b>FBIO PDUFA Dates</b></dt>
    <dd>October 10th</dd>




<span class="research-container"><h3>Links</h3>
	<span><a class="research-container" href="https://www.fortressbiotech.com/" target="_blank" >Company Website</a></span>
	<span><a class="research-container" href="https://finance.yahoo.com/quote/FBIO?p=FBIO" target="_blank">Yahoo Fiance</a></span>
	<span><a class="research-container" href="https://stocktwits.com/symbol/FBIO" target="_blank">StockTwits</a></span>
	<span><a class="research-container" href="https://www.tradingview.com/symbols/NASDAQ-FBIO/?utm_campaign=mini-symbol-overview&utm_medium=widget_new" target="_blank">TradingView</a></span>
	<span><a class="research-container" href="https://www.biopharmcatalyst.com/" target="_blank">BioPharmCatalyst.com</a></span>
	</center>
</span>
<p><hr></p>

<h2 align="center">Zosano Pharma Corp</h2>

<center>
<!-- TradingView Widget BEGIN -->
<div class="tradingview-widget-container">
<div class="tradingview-widget-container__widget"></div>
<div class="tradingview-widget-copyright"><a href="https://www.tradingview.com/symbols/NASDAQ-ZSAN/" rel="noopener" target="_blank"></a></div>
<script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-symbol-info.js" async>
{
"symbol": "NASDAQ:ZSAN",
"width": 1000,
"locale": "en",
"colorTheme": "light",
"isTransparent": false

}
</script>
</div>
<!-- TradingView Widget END -->
</center>
<p>
	<b>Z</b>osano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology.
	Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
	<i>Source Fidelity.com</i>  </p>
<center>
<div>
<div class="pdufa-container"><b>ZSAN PDUFA Dates</b>
	<div><a class="pdufa-container" href="https://finance.yahoo.com/news/zosano-pharma-receives-preliminary-fda-214000619.html"style="color:red;">October 20th Denied September 30th</a></div>
</div>


<span class="research-container"><h3>Links</h3>
<span><a class="research-container" href="https://www.zosanopharma.com/" target="_blank" >Company Website</a></span>
<span><a class="research-container" href="https://finance.yahoo.com/quote/ZSAN?p=ZSAN" target="_blank">Yahoo Fiance</a></span>
<span><a class="research-container" href="https://stocktwits.com/symbol/ZSAN" target="_blank">StockTwits</a></span>
<span><a class="research-container" href="https://www.tradingview.com/symbols/NASDAQ-ZSAN/?utm_campaign=mini-symbol-overview&utm_medium=widget_new" target="_blank">TradingView</a></span>
<span><a class="research-container" href="https://www.biopharmcatalyst.com/" target="_blank">BioPharmCatalyst.com</a></span>
</center>
</span>
<hr>
<h2 align="center">SPECTRUM PHARMACEUTICALS INC</h2>

<p>
<center>
	<!-- TradingView Widget BEGIN -->
<div class="tradingview-widget-container">
  <div class="tradingview-widget-container__widget"></div>
  <div class="tradingview-widget-copyright"><a href="https://www.tradingview.com/symbols/NASDAQ-SPPI/" rel="noopener" target="_blank"></a></div>
  <script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-symbol-info.js" async>
  {
  "symbol": "NASDAQ:SPPI",
  "width": 1000,
  "locale": "en",
  "colorTheme": "light",
  "isTransparent": false
}
  </script>
</div>
</center>

<p>	<b>S</b>pectrum Pharmaceuticals, Inc., a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS,
a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with
various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's
lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology
 license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for focused interferon therapeutics drug delivery platform.
 The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is
 headquartered in Henderson, Nevada. <i>Source Fidelity.com</i>  </p>

<center>
<div class="pdufa-container">
  <div class="pdufa-container"><b>SPPI PDUFA Dates</b></div>
  <div class="pdufa-container">October 24th</div>
</div>

  <span class="research-container"><h3>Links</h3>
		<span><a class="research-container" href="https://www.sppirx.com/" target="_blank">Company Website</a></span>
		<span><a class="research-container" href="https://finance.yahoo.com/quote/SPPI?p=SPPI" target="_blank">Yahoo Fiance</a></span>
		<span><a class="research-container" href="https://stocktwits.com/symbol/SPPI" target="_blank">StockTwits</a></span>
		<span><a class="research-container" href="https://www.tradingview.com/symbols/NASDAQ-SPPI/?utm_campaign=mini-symbol-overview&utm_medium=widget_new" target="_blank">TradingView</a></span>
		<span><a class="research-container" href="https://www.biopharmcatalyst.com/" target="_blank">BioPharmCatalyst.com</a></span>
		</center>
	</span>
	<hr>
	<h2>ETON PHARMACEUTICALS INC</h2>
	</center>

	<center>
	<div class="tradingview-widget-container">
		<div class="tradingview-widget-container__widget"></div>
		<div class="tradingview-widget-copyright"><a href="https://www.tradingview.com/symbols/NASDAQ-ETON/" rel="noopener" target="_blank"></a></div>
		<script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-symbol-info.js" async>
		{
		"symbol": "NASDAQ:ETON",
		"width":1000,
		"locale": "en",
		"colorTheme": "light",
		"isTransparent": false
	}
		</script>
	</div>
	</center>

	<p>
		<b>E</b>ton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. The company offers Biorphen,
		a phenylephrine hydrochloride injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
		It also develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-203, which is injectable product candidates for use in the hospital
		setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101 and ET-104, which are oral liquid product candidates for neurological indications; DS-300
		and DS-100, which are injectable product candidates; and ET-105, a lamotrigine for oral suspension. Eton Pharmaceuticals, Inc. was founded in 2017 and is based in Deer Park, Illinois.
		<i>Source Fidelity.com</i>
	</p>
	<center>
		<div class="pdufa-container"><b>ETON PDUFA Dates</b>
			<div><a class="pdufa-container" href="https://finance.yahoo.com/news/fda-approves-bausch-lomb-alaway-120000104.html" target="_blank" style="color:green;">September 15th - Delayed Approved on Septemer 25th</a></div>
			<div><a class="pdufa-container" href="https://finance.yahoo.com/news/eton-pharmaceuticals-announces-fda-approval-225000380.html" target="_blank" style="color:green;">September 29th - Approved on Septemer 30th</a></div>
			<div><a class="pdufa-container" >Awaiting FDA announcement in October. No exact date given.</a></div>
		</div>
	</center>

	<center>
	<span class="research-container"><h3>Links></h3>
		<span><a class="research-container" href="https://etonpharma.com/" target="_blank" >Company Website</a></span>
		<span><a class="research-container" href="https://finance.yahoo.com/quote/ETON?p=ETON" target="_blank">Yahoo Fiance</a></span>
		<span><a class="research-container" href="https://stocktwits.com/symbol/ETON" target="_blank">StockTwits</a></span>
		<span><a class="research-container" href="https://www.tradingview.com/symbols/NASDAQ-ETON/?utm_campaign=mini-symbol-overview&utm_medium=widget_new" target="_blank">TradingView</a></span>
		<span><a class="research-container" href="https://www.biopharmcatalyst.com/" target="_blank">BioPharmCatalyst.com</a></span>
	</span>
	</center>

	</body>
</html>
